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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the safety and efficacy of intermittent prophylactic antibiotics in the treatment of adults and children with bronchiectasis.
B A C K G R O U N D
Description of the condition
Bronchiectasis is a common but, until recently, underdiagnosed
chronic disorder characterised by permanent dilation of the
large airways, bronchi and bronchioles (branches of the bronchi)
(Pasteur 2010). This arises from a vicious cycle of respiratory in-
fections that cause inflammation and damage to the bronchial
walls, leading to disordered mucociliary clearance (mucus-clear-
ing mechanism of the bronchi), that in turn renders patients more
susceptible to recurrent infections (Chalmers 2013; Cole 1986).
An understanding of this cycle of recurrent infection and tissue
destruction is important in the management of bronchiectasis,
where the central aim is to limit the progression of lung injury
by arresting inflammation and bacterial colonisation (Cole 1997;
Pasteur 2010). The most commonly isolated microorganisms in-
clude non-typeable Haemophilus influenzae, Pseudomonas aerugi-
nosa, Streptococcus pneumoniae, Staphylococcus aureus andMoraxella
catarrhalis (Foweraker 2011). Organisms such as P. aeruginosa,H.
influenzae and M. catarrhalis are often resistant to antimicrobial
therapy arising from intrinsic resistance mechanisms and frequent
exposure to antimicrobial agents (Menendez 2017).
Bronchiectasis presents with chronic, persistent cough, produc-
tive phlegm that is frequently difficult to expectorate, and re-
current respiratory infections, posing a significant health burden
(Chalmers 2014). The cause of around half of presenting cases are
unknown and classified as idiopathic (cause is unknown), but the
most common aetiology is post-infectious bronchiectasis, a diverse
group that includes people with childhood respiratory infections
such as pertussis, bacterial pneumonia, or tuberculosis (Pasteur
2010). Diagnosis is based on the presence of one or more abnor-
mally dilated bronchi using high resolution computed tomogra-
phy (HRCT) (Chang 2010; Pasteur 2010). The central aims of
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therapeutic management are to reduce symptoms such as cough,
breathlessness and expectoration, to reduce the frequency and du-
ration of exacerbations, and to improve quality of life (Chalmers
2015; Pasteur 2010).
Recent epidemiological studies have suggested that the prevalence
of bronchiectasis is increasing, particularly in women and those
over 60 years old (Roberts 2010; Seitz 2010; Weycker 2005), with
higher rates in low- and middle- income countries (Habesoglu
2011). In Germany, prevalence has been estimated at 67 cases
per 100,000 general population (Ringshausen 2015). Recent UK
figures estimate 263,000 adults living with bronchiectasis in 2013,
with prevalence rates per 100,000 rising by approximately 60%
over a nine-year period, from 350.5 to 566.1 in women and from
301.2 to 485.5 in men (Quint 2016). Similarly, approximately
15,000 new cases were identified in 2013, with incidence rates
per 100,000 person-years rising by around 63% over the same
nine year period, from 21.2 to 35.2 in women and from 18.2 to
26.9 in men. European mortality rates, based on 2005 to 2009
data, are estimated at 0.3 per 100,000 general population in EU
countries and at 0.2 per 100,000 general population in nine non-
EU countries (Gibson 2013). Age-adjusted mortality in the UK is
estimated to be 2.3 times higher in women and 2.1 times higher
in men compared to the general population (Quint 2016).
The impact of bronchiectasis on children is significant, with worse
quality of life in younger children and those with more frequent
exacerbations (Kapur 2012). Global prevalence is highly variable
with higher rates in some indigenous groups, such as 15 per 1000
in Australian Aboriginal and Torres Strait Islander children and
16 per 1000 among southwest Alaskan children (Chang 2002).
The incidence rate in one NewZealand study was 3.7 per 100,000
per year in under 15 year olds, with an overall prevalence of 1
per 3000 children, but a much higher rate of 1 per 625 in Pacific
children (Twiss 2005). These rates were almost seven times higher
than those in Finland (Twiss 2005).
Higher prevalence rates may be attributable to improvements in
diagnosis resulting from high resolution CT (HRCT) scans and
heightened awareness of bronchiectasis symptoms, rather than a
true increase in the spread of the condition (Goeminne 2016).
Bronchiectasis is associated with a high rate of exacerbations, hos-
pital admissions, and attributable mortality, which places a con-
siderable burden on international healthcare systems (Chalmers
2015; Redondo 2016). Approximately half of patients on the Eu-
ropean bronchiectasis registry have at least two exacerbations per
year and a third of those on the registry are hospitalised at least
once a year (Polverino 2017). Patients with more frequent annual
exacerbations and those colonised with P. aeruginosa have a more
rapid decline in lung function, worse health-related quality of life
and a higher risk of hospitalisation and mortality (Evans 1996;
Martínez-García 2007; Polverino 2017;Wilson 1997). Other risk
factors for higher hospitalisation and mortality rates include; se-
vere exacerbations, low body mass index, chronic bacterial infec-
tion, low forced expiratory volume in one second (FEV1) per-
cent of predicted, a higher proportion of affected lobes, and more
breathlessness (Chalmers 2014; Rogers 2014; Seitz 2010).
The high burden of bronchiectasis is associated with substantial
costs of care. The annual mean direct medical costs for an adult
with bronchiectasis was estimated at EUR4671 in a Spanish study,
with higher costs associated with more severe disease (De la Rosa
2016). In a USA-based study, the additional costs of care for
bronchiectasis patients compared to matched case-controls were
associated with an annual increase of USD 2319 in overall costs
and USD 1607 in respiratory-related costs (Joish 2013).
Bronchiectasis is the primarymanifestation of genetic diseases such
as cystic fibrosis, primary ciliary dyskinesia (impaired movement)
or hypogammaglobulinaemia (immune disorder characterised by
reduced resistance to infection). Such cases are characterised by
more severe clinical presentation and worse outcomes and are be-
yond the scope of this systematic review. Bronchiectasis is also asso-
ciated with other diseases, such as chronic obstructive pulmonary
disease (COPD). Patients with both COPD and bronchiectasis
have worse outcomes, especially those who continue to smoke,
and are therefore regarded as a separate population and beyond
the remit of this review (Lanza 2018, Ni 2015).
Description of the intervention
Prophylactic antibiotic therapy is a cornerstone of the manage-
ment of patients with bronchiectasis, its goal being to suppress
bacterial infection and to break the vicious cycle of recurrent infec-
tions and exacerbations, with resultant reductions in bacterial load,
inflammation, and consequent tissue destruction of the airways
(Chalmers 2012). To date, randomised controlled trials (RCTs) of
antibiotics in bronchiectasis have evaluated different modes (oral,
intravenous (IV) and inhaled) and methods (continuous versus
intermittent) of administration, using different classes of antibi-
otics, including but not limited to macrolides, quinolones, and
polymyxins. Pooled data on the use of long-term prophylactic
antibiotics administered for three or more months have demon-
strated antibiotics efficacy for patients with frequent bronchiecta-
sis exacerbations in decreasing the frequency and severity of exac-
erbations, increasing the time to first exacerbation and reducing
symptom burden, offset by an increased adverse event profile and
increased bacterial resistance (Hnin 2015; Polverino 2017). Con-
tinuous antibiotics are associated with more than three times the
risk of bacterial resistance compared to no antibiotic prophylactic
therapy (Hnin 2015).
In clinical practice, antibiotics are most frequently used in patients
with three or more exacerbations per year, in patients with chronic
P. aeruginosa infection and also in patients with less frequent ex-
acerbations who continue to have significant impairment of qual-
ity of life despite standard treatment (Chalmers 2015; Polverino
2017). Intermittent therapy refers to the repeated prophylactic
administration of courses of antibiotics with predefined duration
and intervals. Examples include antibiotics given every month or
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drug holidays with treatment during the winter months only to
allow for seasonal variations. As the half-life of antibiotics, such
as azithromycin, is approximately one week, the off-treatment in-
terval should last at least 14 days. Prophylactic antibiotics may be
given for regimens of at least 14 days on-treatment followed by at
least 14 days off-treatment, for cycles lasting at least three months
(Polverino 2017). In this review, we will compare the administra-
tion of intermittent long-term antibiotics using different duration
periods, or compared with placebo, over three months or longer.
This definition excludes short courses of antibiotics for acute exac-
erbations, which have been addressed in a separate review (Wurzel
2011).
How the intervention might work
Chronic airway infection is central to the pathogenesis (devel-
opment) of bronchiectasis. The presence of airway bacteria re-
sults in neutrophilic (white blood cells) inflammation which pro-
motes airway destruction and disease progression (Chalmers 2012;
Chalmers 2017). It is therefore logical that suppression of bacte-
rial load should reduce symptoms and prevent exacerbations. An-
tibiotic treatment has been proven to reduce bacterial load and
to thereby reduce neutrophilic inflammation (Chalmers 2012).
Gram-negative pathogens and P. aeruginosa, in particular, are as-
sociated with a significant increase in the risk of death over five
years compared to other pathogens, even after adjustment for con-
founders (Araujo 2018; Finch 2015).
As clinical outcomes are better in patients without bacterial infec-
tion, continuous long-term suppression of airway bacteria is an
important aim (Polverino 2017). However, the argument against
continuous exposure to antibiotics is that it leads to increased bac-
terial resistance and consequently treatment may lose its effec-
tiveness (Chalmers 2015). On the contrary, intermittent admin-
istration of antibiotics might remove or limit antibiotic selection
pressure and, consequently, prevent the development of resistance.
There is often a fitness cost for bacteria acquiring antimicrobial
resistance which means that once the selection pressure is removed
the resistant organism is ’out-competed’ by non-resistant organ-
isms (Melnyk 2015). Indirect evidence of this concept is provided
by a large retrospective analysis ofmechanically-ventilated patients
with hospital-acquired (nosocomial) infections (40% chronic lung
disease) where an interval of at least 20 days between serial courses
of antibiotics was associated with a 24% reduction in development
of resistance (Hui 2013). Additionally, some antibiotic agents ap-
pear to have problems with tolerability and an increased risk of
antibiotic-related adverse events which may be minimised with
intermittent therapy. Also, the treatment burden associated with
nebulised therapies (inhaled as a mist), including both the time to
administer the dose and to care for the machinery, are substantial
and so less frequent administration may improve treatment adher-
ence and limit total costs (Chalmers 2015; McCullough 2014).
Why it is important to do this review
The 2017 ERS (European Respiratory Society) guidelines for
bronchiectasis recommended the use of long-term antibiotics for
patients with three or more exacerbations per year following treat-
ment of the underlying cause and regular airway clearance exer-
cises (Polverino 2017). There are currently no clinical trials that
compare the safety and efficacy of continuous administration with
intermittent administration of antibiotics (Donovan 2018) and
the optimal delivery route (oral, inhaled, IV), dosage, and dura-
tion of intermittent antibiotics remain unclear. Given the theoret-
ical balance between bacterial suppression and prevention of resis-
tance, it is important to synthesise the available data on the safety
and efficacy of intermittently administered antibiotic treatments
in bronchiectasis to determine their impact on the prevention of
exacerbations.
O B J E C T I V E S
To evaluate the safety and efficacy of intermittent prophylactic
antibiotics in the treatment of adults and children with bronchiec-
tasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised and cluster-randomised controlled
trials (RCTs). We will also include cross-over studies but, to over-
come potential carry-over effects from the first phase (e.g. antibi-
otic resistance), we will only use data from the first pre-cross-over
phase. We will include studies reported in full text, those only
published as abstracts, and unpublished data.
Types of participants
We will include adults and children (< 18 years) with a clinical di-
agnosis of bronchiectasis confirmed by high resolution computed
tomography (HRCT), plain film chest radiograph, or bronchog-
raphy and a documented history of recurrent chest infections. We
will exclude studies where participants received high dose antibi-
otics immediately prior to enrolment or those with a diagnosis
of allergic bronchopulmonary aspergillosis (ABPA), hypogamma-
globulinaemia, cystic fibrosis (CF), sarcoidosis, or a primary diag-
nosis of COPD. We will also exclude studies where participants
receive short courses of antibiotics for an acute exacerbation. We
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will only include studies with mixed populations (different res-
piratory conditions), if there is a separate subgroup analysis for
participants with bronchiectasis. Data on children and adults will
be analysed separately.
Types of interventions
We will include studies comparing the following:
• Prophylactic intermittent antibiotics versus placebo.
• Prophylactic intermittent antibiotics versus usual care.
Usual care may include bronchodilators, anti-inflammatories,
mucolytics, inhaled hyperosmolar agents, or chest physiotherapy.
• Prophylactic intermittent antibiotics using regimen X versus
regimen Y, e.g. 14 days of antibiotics followed by 14 days of
none versus 28 days of antibiotics followed by 28 days of none.
These different comparisons will be reported separately. Intermit-
tent prophylactic administration is defined as repeated courses of
antibiotics with predefined on-treatment duration of at least 14
days and off-treatment intervals of at least 14 days, for a study
duration of at least three months. The method of administration
may be oral or inhaled, but should be the same in all study groups
in order to isolate the effect of the antibiotic rather than the deliv-
ery device. We will exclude studies that compare continuously ad-
ministered prophylactic antibiotics with those administered inter-
mittently as this has been addressed in a separate review (Donovan
2018).
Types of outcome measures
We will use exacerbation and hospitalisation rates as reported by
study authors. We will collect outcome data at a range of follow-
up points that best reflect available evidence from included studies
(e.g. end of study, end of follow-up, change from baseline).
Primary outcomes
1. Frequency of exacerbations (defined using study authors’
criteria).
2. Serious adverse events defined as follows: adverse events
resulting in death or life-threatening events, hospitalisation or
prolongation of existing hospitalisation, persistent or significant
disability or congenital anomalies, or events considered
medically important (Hansen 2015).
Secondary outcomes
1. Time to first exacerbation (defined using study authors’
criteria).
2. Duration of exacerbations (defined using study authors’
criteria).
3. Severity of exacerbations (defined using study authors’
criteria).
4. Development of antibiotic resistance (defined using study
authors’ criteria).
5. Frequency of hospital admissions due to exacerbations
(defined using study authors’ criteria).
6. Frequency of hospital admissions (defined using study
authors criteria).
7. Lung function measured as forced expiratory volume in one
second (FEV ).
8. Health-related quality of life using measures validated in a
clinical setting (e.g. St George’s Respiratory Questionnaire
(SGRQ), Leicester Cough Questionnaire (LCQ) or Quality of
Life-Bronchiectasis (QoL-B)).
9. Adverse effects and adverse reactions defined as follows.
Adverse effects are unwanted outcomes of which the patient is
not aware, usually detected by laboratory tests (e.g. biochemical,
haematological, immunological, radiological, pathological tests)
or clinical investigations (e.g. gastrointestinal endoscopy, cardiac
catheterisation). Adverse reactions are unwanted outcomes that
the patient experiences and are detected by their clinical
manifestations (symptoms and/or signs) (Hansen 2015).
The above outcomes will not be not used as eligibility criteria for
inclusion of studies in the review. Study selection will be based on
types of studies, participants, and interventions, to avoid excluding
eligible studies with unpublished review outcomes.
Search methods for identification of studies
Electronic searches
Wewill identify studies from theCochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identified
from several sources:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org);
2. weekly searches of MEDLINE Ovid SP 1946 to date;
3. weekly searches of Embase Ovid SP 1974 to date;
4. monthly searches of PsycINFO Ovid SP 1967 to date;
5. monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature) 1937 to date;
6. monthly searches of AMED EBSCO (Allied and
Complementary Medicine);
7. handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings are in Appendix 1. See Appendix 2 for search terms used
to identify studies for this review.
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We will search the following trials registries:
1. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov);
2. World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch).
Wewill search theCochrane Airways Trials Register and additional
sources from inception to present, with no restriction on language
of publication.
Searching other resources
We will check the reference lists of all primary studies and review
articles for additional references and search relevantmanufacturers’
websites for study information.
We will also search for errata or retractions from included studies
published in full text on PubMed and report the date of the search
in the review.
Data collection and analysis
Selection of studies
Two review authors (TD and MMD) will screen the titles and
abstracts of the search results independently and code them as ’re-
trieve’ (eligible or potentially eligible/unclear) or ’do not retrieve’.
We will retrieve the full-text study reports of all potentially eli-
gible studies and two review authors (TD and MMD) will in-
dependently screen them for inclusion, recording the reasons for
exclusion of ineligible studies. We will resolve any disagreement
through discussion or, if required, we will consult a third person/
review author (SS). We will identify and exclude duplicates and
collate multiple reports of the same study so that each study, rather
than each report, is the unit of interest in the review.Wewill record
the selection using a PRISMA flow diagram and ’Characteristics
of excluded studies’ table (Moher 2009).
Data extraction and management
We will use a data collection form for study characteristics and
outcome data, which has been piloted on at least one study in the
review. One review author (AT) will extract the following study
characteristics from included studies:
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for studies and notable conflicts of interest
of trial authors.
We will summarise the interventions in included studies (study,
adults or children, number of participants, type of antibiotic, dose,
frequency, regimen, delivery mode, comparator) using a study
characteristics table.
Two review authors (AT and GP) will independently extract out-
come data from included studies. We will note in the ’Character-
istics of included studies’ table if outcome data were not reported
in a usable way. We will resolve disagreements by consensus or by
involving a third person/review author (SS). One review author
(AT) will transfer data into the Review Manager file (RevMan
2014). We will double-check that data are entered correctly by
comparing the data presented in the systematic review with the
study reports. A second review author (GP) will spot-check study
characteristics for accuracy against the study report.
Assessment of risk of bias in included studies
Two review authors (SS and TD) will assess risk of bias indepen-
dently for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another author (MMD). We will assess the risk of bias according
to the following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
We will judge each potential source of bias as high, low, or un-
clear and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the ’risk of bias’ judgements across different studies for
each of the domains listed. We will consider blinding separately
for different key outcomes, where necessary (e.g. for unblinded
outcome assessment, risk of bias for all-cause mortality may be
very different than for a patient-reported pain scale). Where in-
formation on risk of bias relates to unpublished data or correspon-
dence with a trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic review
We will conduct the review according to this published protocol
and justify any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
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Measures of treatment effect
We will analyse dichotomous data as odds ratios (OR) and con-
tinuous data as the mean difference (MD) or standardised mean
difference (SMD). If data from rating scales are combined in a
meta-analysis, we will ensure they are entered with a consistent
direction of effect (e.g. lower scores always indicate improvement).
We will undertake meta-analyses only where this is meaningful;
that is, if the treatments, participants and the underlying clinical
question are similar enough for pooling to make sense.
We will describe skewed data narratively (for example, as medians
and interquartile ranges for each group).
Where multiple trial arms are reported in a single study, we will
include only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) are combined in the
samemeta-analysis, wewill either combine the active arms or halve
the control group to avoid double-counting.
We will use adjusted date as first choice if it is available (e.g.
rate ratios from Poisson regression models, mean differences from
ANOVAs or results from cluster-RCTs adjusted for the effects of
clustering), followed by change scores and endpoint scores.
We will use intention-to-treat (ITT) analyses where they are re-
ported instead of completer or per protocol analyses.
Unit of analysis issues
For dichotomous outcomes, we will use participants, rather than
events, as the unit of analysis (i.e. number of people admitted to
hospital, rather than number of admissions per person). However,
if exacerbations and hospitalisations are reported as rate ratios
(number of events experienced by a participant) in a study, we will
analyse them on this basis.
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data, where possible (e.g. when a study is identified as an abstract
only). Where this is not possible, and the missing data are thought
to introduce serious bias, we will take this into consideration in
the GRADE rating for affected outcomes.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
studies in each analysis. If we identify substantial heterogeneity (>
50%) we will report it and explore the possible causes by prespec-
ified subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small study and publi-
cation biases.
Data synthesis
We will use a random-effects model, reported with 95% confi-
dence intervals (CI) and perform a sensitivity analysis with a fixed-
effect model. We will synthesise and report dichotomous and con-
tinuous data separately for each outcome, e.g. hospitalisation/no
hospitalisation or duration of hospitalisation. Data on adults and
children will be reported separately. Odds ratios will also be anal-
ysed and reported separately. For a given outcome measure, we
will combine effect estimates, such as differences at endpoint and
change from baseline, providing that there are no reported base-
line differences between groups, When outcomes are measured
using different scales, e.g. health-related quality of life, we will use
standardised mean differences (SMD) in the analyses. We will use
the baseline standard deviation (SD) for the SMD analyses.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the follow-
ing outcomes: frequency of exacerbations, serious adverse events,
development of antibiotic resistance, frequency of hospital ad-
missions, and health-related quality of life. We will use the five
GRADE considerations (risk of bias, consistency of effect, impre-
cision, indirectness, and publication bias) to assess the quality of
the evidence as it relates to the studies that contribute data for the
prespecified outcomes. We will use the methods and recommen-
dations described in Section 8.5 and Chapter 12 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
using GRADEpro software (GRADEpro GDT). We will justify
all decisions to downgrade the quality of studies using footnotes
and we will make comments to aid the reader’s understanding of
the review, where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses:
1. Colonisation with P aeruginosa at study enrolment versus
no colonisation;
2. Method of administration (oral versus IV versus inhaled).
We will use the following outcomes in subgroup analyses:
1. Exacerbation frequency;
2. Serious adverse events.
We will use the formal test for subgroup interactions in Review
Manager (RevMan 2014).
Sensitivity analysis
We plan to carry out sensitivity analyses by comparing results
before and after removing studies at high risk of bias from:
1. Random sequence generation;
2. Allocation concealment.
We will also compare the results from a fixed-effect model with
results from the random-effects model.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Trials Register
Electronic searches: core databases
Database Dates searched Frequency of search
CENTRAL (via the Cochrane Register of
Studies (CRS))
From inception Monthly
MEDLINE (Ovid) 1946 onwards Weekly
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(Continued)
EMBASE (Ovid) 1974 onwards Weekly
PsycINFO (Ovid) 1967 onwards Monthly
CINAHL (EBSCO) 1937 onwards Monthly
AMED (EBSCO) From inception Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the Cochrane Airways Trials Register
Bronchiectasis search
1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (ciliary adj3 dyskinesia).mp.
6. (bronchial$ adj3 dilat$).mp.
7. or/1-6
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Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant studies from the Cochrane Airways Trials Register
Search line Search terms Comments
#1 BRONCH:MISC1 MISC1 denotes the field in the record where the record
has been coded for condition, in this case, bronchiectasis
#2 MeSH DESCRIPTOR Bronchiectasis Explode All Index term for bronchiectasis, exploded to retrieve all nar-
rower terms
#3 bronchiect*
#4 #1 or #2 or #3 search line combines all population terms
#5 MeSH DESCRIPTOR Anti-Bacterial Agents Explode 1 Index term for antibiotics, exploded to retrieve all narrower
terms
#6 antibiotic* or anti-biotic*
#7 anti-bacteri* or antibacteri*
#8 *cillin
#9 *mycin OR *micin
#10 *oxacin
#11 *tetracycline
#12 macrolide*
#13 quinolone*
#14 trimethoprim
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(Continued)
#15 ceph*
#16 sulpha*
#17 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
or #14 or #15 or #16
search line combines all intervention terms
#18 #4 and #17 search line brings together population and intervention
terms
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